SOPHiA GENETICS Launches New Residual Acute Myeloid (RAM) Application

Rhea-AI Summary

SOPHiA GENETICS has announced the launch of its new Residual Acute Myeloid (RAM) Application, aimed at enhancing measurable residual disease (MRD) testing. This application is designed to support the monitoring of Acute Myeloid Leukemia (AML), one of the most common types of leukemia in adults. Over 50% of AML patients relapse within three years of remission, making post-treatment monitoring critical. The RAM Solution, part of SOPHiA's DDM Platform, offers next-generation sequencing (NGS)-based MRD testing with high sensitivity, detecting one cancer cell among 10,000. This tool provides longitudinal variant monitoring, comprehensive MRD reports, and rapid results within four days. The solution will be available globally this summer and aims to improve patient outcomes by detecting early signs of relapse.

Positive

• Launch of new RAM Application expanding oncology portfolio.
• High sensitivity NGS-based MRD testing detects one cancer cell among 10,000.
• Provides longitudinal variant monitoring and comprehensive MRD reports.
• Rapid MRD results available within four days.
• Global availability planned for this summer.

Negative

• No specific financial data or revenue projections provided.
• No information on the cost or pricing of the new application.

Novel application supports measurable residual disease (MRD) testing to help monitor cancer and stay ahead of relapse

BOSTON and ROLLE, Switzerland, June 24, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced its new Residual Acute Myeloid (RAM) Application. The new offering expands the company's comprehensive oncology portfolio to support measurable residual disease (MRD) capabilities and will be available to customers worldwide this summer.

Acute Myeloid Leukemia (AML) represents about one percent of all cancers worldwide, yet is one of the most common forms of leukemia in adults¹. Over 50 percent of AML patients relapse within 3 years after achieving complete remission², therefore post-treatment monitoring is imperative for AML patients, particularly within the first two years, to help quickly detect any signs of relapse³. MRD solutions can help inform post-remission therapy and identify early relapse, and serve as a primary endpoint in clinical trials, helping researchers detect even the smallest trace of cancer and support better patient outcomes.

"AML unfortunately still remains an area of high unmet medical need today, with associated suboptimal patient outcomes. MRD measurement and monitoring has a critical role to play, for example by enabling research into the most optimal sequencing of therapies," said Philippe Menu, M.D., PhD., Chief Medical Officer and Chief Product Officer, SOPHiA GENETICS. "We are proud to contribute to the fight against AML through our SOPHiA DDM™ RAM Solution. In particular we feel that the capability to seamlessly track longitudinally the evolution of individual mutations over time through a dedicated add-on module of our SOPHiA DDM™ Platform has the potential to be a game-changer for clinical researchers."

Next-generation sequencing (NGS)-based MRD testing is among the most advanced in cancer screening and monitoring, and can be found only with highly sensitive methods. The SOPHiA DDM™ RAM Solution provides users with the confidence that MRD will detect even one cancer cell among 10,000 cells. This application will allow users to stay ahead of disease response with the analytical capabilities of the SOPHiA DDM™ Platform, enabling sensitive variant detection down to 0.01% VAF and covering guideline-recommended genes to deliver robust insights for residual acute myeloid.

Customers using the SOPHiA DDM™ RAM Solution will have access to longitudinal variant monitoring, allowing them to visualize the mutational landscape for each patient and its evolution over time. The solution also provides users with the most up-to-date databases and customizable reporting features to generate graphical representations and comprehensive MRD reports.

Additionally, the SOPHiA DDM™ RAM Solution will continually hone its machine learning algorithms to provide the most accurate MRD results in just four days.

Representatives from SOPHiA GENETICS are available at AMP (Association for Molecular Pathology) Europe June 24-27 to discuss AML monitoring with this new application.

For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.com and connect on LinkedIn.

About SOPHiA GENETICS  
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.com and connect with us on LinkedIn. 

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence. 

SOPHiA GENETICS Forward-Looking Statements: 
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. 

1 https://www.cancer.org/cancer/types/acute-myeloid-leukemia/about/key-statistics.html
2 www.leukaemiacare.org.uk
3 https://onlinelibrary.wiley.com/doi/full/10.1111/apm.12926

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-launches-new-residual-acute-myeloid-ram-application-302179525.html

SOURCE SOPHiA GENETICS

FAQ

What is SOPHiA GENETICS' new RAM Application?

The RAM Application is a new tool by SOPHiA GENETICS for measurable residual disease (MRD) testing in Acute Myeloid Leukemia (AML).

When will the SOPHiA GENETICS RAM Solution be available?

The RAM Solution will be available globally this summer.

What is the detection capability of the SOPHiA GENETICS RAM Application?

The RAM Application can detect one cancer cell among 10,000 cells.

How quickly can results be obtained with the SOPHiA GENETICS RAM Solution?

MRD results can be obtained within four days with the RAM Solution.

Why is post-treatment monitoring essential for AML patients?

Over 50% of AML patients relapse within three years of remission, making post-treatment monitoring critical to detect early signs of relapse.